Business Wire

CA-DENODO

Share
Denodo’s 2020 User Conference DataFest Draws a Record 1,800 Global Attendees Exploring Hybrid/Multi-Cloud, Cloud Integration, Data Fabric, Data Science & AI/ML

Denodo , the leader in data virtualization, today announced a record attendance of nearly 1,800 at its annual user conference, DataFest 2020 which was held across the NA, EMEA, and APAC regions. This year’s virtual DataFest events hosted some of the most well recognized data luminaries and subject matter experts, who immersed themselves in topics such as hybrid/multi-cloud strategies, cloud data integration, data science and AI/ML, among others. Attendees made up of Denodo customers, partners, and analysts chose the winners of Denodo’s annual Data Innovation Awards at each event, to recognize some of the exemplary use cases of logical data fabric created with data virtualization technology as the foundation.

All of the session presentations are now available for on-demand viewing, here .

“Our heartiest congratulations go out to all the winners and finalists of our Data Innovation Awards,” said Ravi Shankar, senior vice president and chief marketing officer at Denodo. “Recognizing these customers is the least we can do, as these organizations and individuals set the standard for the future of data management and exemplify some of the best use cases of logical data fabric. As we push the envelope with continuous product innovations , our customers showcased how those advancements can be put to work for even more impressive and valuable use cases.”

Like past events, this year included an esteemed panel of subject matter experts, who distilled through a slew of customer use cases to choose the finalists for each Data Innovation Award. All Denodo customers were considered for the Data Innovation Award with the winners acknowledged for demonstrating best practices, business impact, and novel implementations. The selection process highlights the many innovative uses of data virtualization at actual customer sites and provided attendees with metrics to validate its importance.

“I am absolutely thrilled to receive this year’s Data Innovation Award for the EMEA region,” said Olav Lognvik, Solution Architect at DNB. “Denodo has been the central piece in our cutting-edge data platform that supports data science use cases such as the one for mobile banking. We are glad to be able to share our success story with hundreds of data virtualization enthusiasts and as we broaden our use cases of the Denodo Platform, we hope to share more success stories in the future.”

Winners and finalists of the Denodo Data Innovation Awards 2020 include:

North America – Winner Lauren Cordova from Panasonic , for its connected car IoT/Edge and cloud analytics use case; finalist Ryan Thompson from Prologis , for their logical data lake use case.

EMEA – Winner Olav Lognvik and Christian Dancke Tuen from DNB , for its data science for mobile banking use case; finalist Tekin Mentes from LeasePlan , for their global data hub for fleet management use case.

APAC – Winner Joshua Fletcher from BHP , for its multi-cloud data fabric for global resource management use case; finalist Johan De Coning from Silver Chain , for their Healthcare with hololens and incident management system use case.

Please tweet: News: #datavirtualization leader Denodo announces the winners of its 3rd annual Data Innovation Awards during #DenodoDataFest 2020. Audience vote @Panasonic, @BHP and @DNB for the most innovative use cases.

About Denodo

Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye